To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
IntelliCell BioSciences Appoints Dr. Sigmund Norr to its Board of Advisors
IntelliCell BioSciences, Inc. has announced that it has appointed pediatrician, Dr. Sigmund Norr to its Board of Advisors. Dr. Norr, of the Cleveland Clinic, joins ten other prominent doctors on the Company's Board of Advisors.
Sigmund Carl Norr, Ph.D., M.D., practices general pediatrics and serves as Section Head of Pediatrics at the Willoughby Hills Family Health Center.
Prior to joining the Cleveland Clinic, Dr. Norr was Medical Director and staff physician at MEDGroup in Fairlawn, Ohio.
Preceding that, Dr. Norr served in a number of roles with Ohio Permanente Medical Group, including Medical Director of the Alcohol Chemical Dependency Program, and Chief of the Department of Pediatric and Adolescent Medicine.
He is board-certified in pediatrics and addiction medicine. Dr. Norr received his undergraduate degree in biology from the University of Pittsburgh.
He completed a doctorate in developmental cell biology at Case Western Reserve University and earned his medical degree from the University of Miami.
He completed an internship and residency in pediatric medicine at Rainbow Babies and Children's Hospital in Cleveland, Ohio.
Dr. Norr is a member of the American Academy of Pediatrics. His specialty interests include ambulatory pediatrics and adolescent medicine, ADHD, asthma, and adolescent chemical dependency. He has published and spoken on the topics of neurobiology and cell biology.
"We welcome Dr. Norr aboard and look forward to what we're sure will be a substantive contribution to IntelliCell given his extensive knowledge of cell biology and pediatric medicine," stated IntelliCell Chairman and CEO, Dr. Steven Victor.
The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia.
Since the middle of 2009 when the US FDA published its laws on autologous stem cells the field has expanded rapidly.
Currently, doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.
